- KE-758, an active metabolite of the new anti-rheumatic drug KE-298, suppresses production of tumor necrosis factor-alpha and interleukin-1 beta in THP-1, a human monocyte cell line. Sugimoto, M., Inoue, T., Yamashita, M., Takeshita, K., Nakaike, S. Drugs under experimental and clinical research. (2002)